TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05202925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Musical Training Program
Description: a weekly 45-minute lesson, one-to-one musical training
Study: NCT04968691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation based exercise treatment
Description: The telerehabilitation group will be shown how to do the exercises online by the researcher before each session, 3 sessions a week for 6 weeks, with mobile telecommunication applications, and it will be ensured that the patients do the exercises correctly and are followed up. In addition, at the beginning of each week, videos with the exercise content of that week will also be sent.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home based exercise treatment
Description: n the study, exercise cards were given to the control group and the exercise treatment they were asked to do at home 3 sessions a week for 6 weeks
Study: NCT04874662

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NAM/B6
Description: Single daily dose administration will take place from Day 0 (V1) to Day 8 (V4) around 8 am after an overnight fast from the subsequent evening at 9 pm.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NAM/B6
Description: Single daily dose administration will take place from Day 0 (V1) to Day 8 (V4) around 8 am after an overnight fast from the subsequent evening at 9 pm.
Study: NCT04846088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: A 7mg nicotine pouch product
Study: NCT05893225

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride 850 mg Oral Tablet
Description: Metformin Hydrochloride oral tablets 850 mg t.i.d. or b.i.d.
Study: NCT05217641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG505 MD39.3 mRNA
Description: Administered by IM injection
Study: NCT04846088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product F
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product F
Description: A 7mg nicotine pouch product
Study: NCT05217641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG505 MD39.3 mRNA
Description: Administered by IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG505 MD39.3 gp151 mRNA
Description: Administered by IM injection
Study: NCT04951388

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901(S protein with adjuvant)
Description: Approximately 330 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MVC-COV1901(Saline)
Description: Approximately 55 participants will receive 2 doses of MVC-COV1901(Saline) at Visit 2 (Day 1) and Visit 4 (Day 29) via IM injection in the deltoid region
Study: NCT06163703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Life Skills Triple P
Description: The intervention is a 12-session program that combines parenting support with trauma-informed life skills coaching. It includes content related to positive parenting strategies, self-regulation, coping with emotions, effective communication, dealing with the past, and developing healthy habits.
Study: NCT04846088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product H
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product H
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product H
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product H
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product H
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product I
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product I
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product I
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product I
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product I
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product I
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product I
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product I
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product I
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product I
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product I
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product I
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product I
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product I
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product I
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product I
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product I
Description: A 7mg nicotine pouch product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product I
Description: A 7mg nicotine pouch product
Study: NCT04822766

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: patients will undergo allo-HSCT after consolidation therapy (or completion of other appropriate non-palliative strategy) according to standard procedures of the transplant center (choice of donor, conditioning regimen, GVHD and infection prophylaxis). The use of novel therapies (such as sorafenib, midaustorine, venetoclax, etc.) will be allowed as post-transplantation maintenance strategy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best chemotherapy treatment
Description: patients will be treated according to the standard procedures of the treating center for this type of population. Patients will receive the best available treatments (including additional conventional chemotherapy or other non-palliative therapies such as 5-azacytidine, decitabine, venetoclax, midaustorine, enasidenib, etc.).
Study: NCT05984537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Participants in the bivalirudin group received a one-time intravenous injection of 0.75 mg/kg during PCI, and then received a continuous intravenous infusion of 1.75 mg/kg/h for 4 hours according to the participants' condition after PCI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard heparin
Description: Participants in the standard heparin group received a one-time intravenous injection of 50 U/kg of standard heparin during PCI.
Study: NCT05893225

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching Metformin Hydrochloride oral tablets t.i.d. or b.i.d.
Study: NCT05262504

Intervention type: DEVICE
Intervention: İntraocular lens implantation
Description: Each participant underwent bilateral sequential cataract surgery and bilateral implantation of a novel non-diffractive EDOF IOL (n=26) or a trifocal IOL (n=26). The interval between the first and second-eye surgeries was 1 to 3 weeks. The patients selected the IOL model after they were fully informed regarding the advantages and disadvantages of each IOL, by their surgeon. Their degree of interest in greater spectacle freedom at far, intermediate, and near distances, as well as their daily activities such as frequency of night driving or reading habits were discussed. The possibility of photic disturbances was described and explained as well.

Intervention type: DEVICE
Intervention: İntraocular lens implantation
Description: Each participant underwent bilateral sequential cataract surgery and bilateral implantation of a novel non-diffractive EDOF IOL (n=26) or a trifocal IOL (n=26). The interval between the first and second-eye surgeries was 1 to 3 weeks. The patients selected the IOL model after they were fully informed regarding the advantages and disadvantages of each IOL, by their surgeon. Their degree of interest in greater spectacle freedom at far, intermediate, and near distances, as well as their daily activities such as frequency of night driving or reading habits were discussed. The possibility of photic disturbances was described and explained as well.
Study: NCT06337006

Intervention type: PROCEDURE
Intervention: Placement of the laryngeal mask airway
Description: Evaluation of patients' chest movement with manual ventilation, airway leak level, airway pressures, fingertip O2 saturation percentage, and capnogram results will be recorded and the correlation between clinical observation and measured parameters will be evaluated.
Study: NCT05947214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Decompression Therapy
Description: Group A will be given myofascial decompression therapy.15 minute's moist heat will be given first. Patient was lied prone on couch with their upper torso unclothed, covered with massage oil than placed cup on skin and suction will created by pump. Than drawn over skin along the spine from cervical to thoracic up to lateral border maintain the suction within skin throughout the procedure. The cup massage will conducted for approximately 10 minutes. Patients were informed that the treatment area may become patchy and there are chances of ecchymosis on the same area.
Study: NCT06296888

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency balloon catheter ablation
Description: Radiofrequency balloon ablation using the HELIOSTAR™ ablation catheter.
Study: NCT05947214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: positional Release Therapy
Description: Group B will be given Positional Release technique (PRT) after application of moist heat pack for 15 minute. The subjects received PRT will be in supine lying with the therapist sitting on the affected side, tender points were located along with the upper fibers of trapezius muscle. The subject's head was laterally flexed towards the side of tender point, then therapist grasps the subject's forearm and abducts shoulder to approximately 90 degree and adds slight flexion or extension to fine-tune. The ideal position of comfort achieved was held for a period of 90 sec and followed by passive return of body part to an anatomically neutral position continued for 5 minutes. Treatment duration was 3 sessions per week for 4 weeks.
Study: NCT05504070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venclose System (digiRF generator w EVSRF catheter)
Description: The Venclose System is intended for use in endovascular coagulation of blood vessels in patients with superficial vein reflux.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venclose MAVEN System (digiRF generator w MAVEN catheter)
Description: The Venclose MAVEN System is intended for use in endovascular coagulation of blood vessels in patients with perforator or tributary vein reflux.
Study: NCT05374395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Recovery Support-Delivered Dropout Prevention enhancement
Description: Peer recovery supports will meet with emerging adults for four weekly sessions plus monthly check-ins during the next two months. Peer recovery supports will engage the emerging adults in motivational and skills-based strategies aimed at increasing adherence to services and attendance to treatment sessions.
Study: NCT06515418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azelaprag (BGE-105)
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azelaprag (BGE-105)
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azelaprag (BGE-105)
Description: Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Placebo for Azelaprag (BGE-105)
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo for Azelaprag (BGE-105)
Description: Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirzepatide
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide Placebo
Description: Subcutaneous Injection
Study: NCT05789199

Intervention type: DRUG
Intervention: Cefiderocol
Description: Cefiderocol is a novel siderophore cephalosporin developed for the treatment of infections caused by Gram-negative bacteria (GNB), including those resistant to carbapenems.
Study: NCT05905445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ozone gel
Description: the activity of omega-3 in the ozone gel may be advantageous as a host-modulating agent in the supplemental treatment of periodontitis
Study: NCT05924256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: SHR-A1811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR 3680 + leuprolide
Description: SHR 3680 + leuprolide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1921
Description: SHR-A1921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: SHR-A1811
Study: NCT04999514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Parenting, Tuning in to Kids
Description: The Mindful Parenting program consists of 8 weekly 2.5-hour group sessions and 3 weekly individual telephone interview sessions (each lasts for around 15-20 minutes). Program materials are translated into Chinese by local partners of the program developer. The Tuning in to Kids program consists of 8 weekly sessions, each lasting for 2.5 hours. Program materials are translated into Chinese.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Parenting, Tuning in to Kids
Description: The Mindful Parenting program consists of 8 weekly 2.5-hour group sessions and 3 weekly individual telephone interview sessions (each lasts for around 15-20 minutes). Program materials are translated into Chinese by local partners of the program developer. The Tuning in to Kids program consists of 8 weekly sessions, each lasting for 2.5 hours. Program materials are translated into Chinese.
Study: NCT05711030

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic paravertebral block multiple (3) injections
Description: already described in arm description

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block single injection
Description: already described in arm description
Study: NCT05358210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blueberry Consumption
Description: Participants will consume 1 cup of frozen blueberries daily for the 12 weeks of the intervention. The study dietitian will provide educational materials and monitor compliance through weekly check-ins. Participants will be instructed to avoid all other high-anthocyanin foods including other berries, cherries, currants, cabbage, red wine, and eggplant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dried Date Consumption
Description: Participants will consume 2-3 dried dates daily for the 12 weeks of the intervention, an isocaloric portion of fruit compared to the blueberry group. The study dietitian will provide educational materials and monitor compliance through weekly check-ins. Participants will be instructed to avoid all other high-anthocyanin foods including blueberries, other berries, cherries, currants, cabbage, red wine, and eggplant.
Study: NCT02095847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-Resolution Microendoscopy Imaging
Description: Once the cervix has been dilated, a hysteroscope will be introduced in the uterine cavity to evaluate for presence of tumor. Location and size of tumor documented. White-light images obtained using the HRME camera introduced through the hysteroscope. Once completed; the hysteroscope will be removed and the uterine cavity will be infused with 10 mL of proflavine (an acridine dye) (0.01% Proflavine (10ml)). A resectoscope will then be introduced in the uterine cavity and fluorescent images obtained using the HRME camera.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine
Description: After hysteroscopy with HRME camera, uterine cavity infused with 10 mL of Proflavine.
Study: NCT06166472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK132
Description: IV infusion, specified dose on specified days.
Study: NCT05832255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin, 1.5 mg
Description: Blister packs will contain five capsules of the study drug, Psilocybin 1.5mg. Subjects will be given blister packs with weekly doses at each visit including baseline (day 1), day 8, day 15, day 21, and day 28. Weekly blister packs will contain five doses (1-2 extra capsules depending on the week) to accommodate for flexibility in scheduling. Unused and open packages will be returned to study staff at each visit after baseline.
Study: NCT04686136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg
Description: Tablets containing 60 mg of Atogepant
Study: NCT05289622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyurethane expandable valve stent implant
Description: The baseline assessment of patients will include the admission of patients and the performance of preoperative exams (cardiological imaging for the correct selection). An estimated surgery time of 5 hours. During the entire procedure, patients will be under general anesthesia and controlled mechanical ventilation. The material collected in the laboratory will be processed, the result released and discarded. After the patient enters the operating room, hemodynamic monitoring, ECG, arterial saturation, with peripheral sensor, central venous access with double lumen catheter will be carried out; blood pressure monitoring by radial artery puncture, bladder catheter and thermometer in the nasopharynx and rectum. After preoperative preparation, patients will undergo a surgical approach by median thoracotomy and installation of the Cardiopulmonary bypass (ECC) circuit, by placing a cannula in the ascending aorta, Superior Vena Cava (SVC) and Inferior Vena Cava (IVC).
Study: NCT05217641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG505 MD39.3 gp151 mRNA
Description: Administered by IM injection
Study: NCT05274932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BFR resistance exercise
Description: 4 sets (30, 15, 15, 15 reps).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BFR resistance exercise
Description: 4 sets (30, 15, 15, 15 reps).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BFR resistance exercise
Description: 4 sets (30, 15, 15, 15 reps).
Study: NCT05217641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG505 MD39.3 gp151 CD4KO mRNA
Description: Administered by IM injection
Study: NCT05100225

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PTP-001
Description: Allogeneic human placental tissue particulate (PTP-001) is administered as a single intra-articular injection to the target knee after resuspension with saline.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PTP-001
Description: Allogeneic human placental tissue particulate (PTP-001) is administered as a single intra-articular injection to the target knee after resuspension with saline.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: The placebo control, physiological saline (0.9% sodium chloride injection, USP), is administered as an intra-articular injection to the target knee.
Study: NCT05194306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perla® Cold Preservation solution
Description: Perla® must be cooled to 2° to 6 °C prior to use. The cold Preservation Solution is used to flush the isolated organ immediately before removal from the donor and/or immediately after removal from the donor. The solution is then left in the organ vasculature during hypothermic storage and transportation.
Study: NCT05745142

Intervention type: DRUG
Intervention: Sunitinib
Description: as provided in real world practice
Study: NCT05244603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ideal binary mask
Description: Speech in noise processed by ideal binary mask to reduce background noise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ideal binary mask
Description: Speech in noise processed by ideal binary mask to reduce background noise
Study: NCT05782543

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normothermic machine perfusion
Description: To determine whether a 4-6 hour period of normothermic machine perfusion, following standard hypothermic machine perfusion, results in better graft function after transplantation, compared to hypothermic machine perfusion preservation alone of kidneys recovered from deceased donors aged 50 years or older
Study: NCT05284825

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 12 Gy in 6 daily fractions
Description: 12 Gy in 6 daily fractions